This study investigates the safety of an investigational radiopharmaceutical in healthy volunteers and patients with pancreatic cancer or other solid tumors. The purpose of this study is to understand how the body processes the investigational radiopharmaceutical.
The study evaluates the safety and biokinetics of the investigational radiopharmaceutical. It looks at how the body absorbs, distributes, and eliminates the substance.
- Who can participate: Participants must be 18 years or older and able to give informed consent. Patients with certain types of cancer, such as pancreatic, lung, or cervical cancer, may be eligible if they have a confirmed diagnosis.
- Study details: Participants will receive a single dose of an investigational radiopharmaceutical through an IV. They will undergo several PET-CT scans to monitor the body's response.
How understandable was the trial content above?
Hard to understand
Easy to understand